7 reports

The company' s key products include Neulasta (pegfilgrastim); Neupogen (filgrastim) indicated for cancer treatment; Enbrel (entanercept) for treating rheumatoid arthritis; Epogen (Erythropoietic Stimulating Agents); Aranesp (darbepoetin alfa) to treat anemia associated with chronic kidn

  • Cholesterol
  • Lipid Modifying Drug
  • United States
  • Product Initiative
  • Amgen Inc.
  • AMARIN'S DYSLIPIDEMIA PORTFOLIO ASSESSMENT, 2015

THE COMPANY HAS A STRONG PRESENCE IN THE RHEUMATOID ARTHRITIS AND ONCOLOGY MARKETS, WITH THE BLOCKBUSTERS ENBREL (ETANERCEPT) AND NEULASTA (PEGFILGRASTIM)/ NEUPOGEN (FILGRASTIM) AS ITS TOP TWO BEST-SELLING THERAPIES IN 2013.

  • Lipid Modifying Drug
  • AstraZeneca PLC
  • Cerenis
  • Merck & Co., Inc.
  • The Medicines Company
  • PIPELINE BY AMGEN INC., H1 2016

The company' s key products include Neulasta (pegfilgrastim); Neupogen (filgrastim) indicated for cancer treatment; Enbrel (entanercept) for treating rheumatoid arthritis; Epogen (Erythropoietic Stimulating Agents); Aranesp (darbepoetin alfa) to treat anemia associated with chronic kidn

  • Cardiovascular Disease
  • Lipid Modifying Drug
  • Therapy
  • United States
  • Product Initiative

The company' s key products include Neulasta (pegfilgrastim); Neupogen (filgrastim) indicated for cancer treatment; Enbrel (entanercept) for treating rheumatoid arthritis; Epogen (Erythropoietic Stimulating Agents); Aranesp (darbepoetin alfa) to treat anemia associated with chronic kidn

  • Endocrine Disease
  • Lipid Modifying Drug
  • United States
  • Company
  • Product Initiative

The company' s key products include Neulasta (pegfilgrastim); Neupogen (filgrastim) indicated for cancer treatment; Enbrel (entanercept) for treating rheumatoid arthritis; Epogen (Erythropoietic Stimulating Agents); Aranesp (darbepoetin alfa) to treat anemia associated with chronic kidn

  • Cardiovascular Disease
  • Lipid Modifying Drug
  • United States
  • Company
  • Product Initiative
  • FAMILIAL HYPERCHOLESTEROLEMIA (TYPE II HYPERLIPOPROTEINEMIA) - PIPELINE BY AMGEN INC., H1 2015

The company' s key products include Neulasta (pegfilgrastim); Neupogen (filgrastim) indicated for cancer treatment; Enbrel (entanercept) for treating rheumatoid arthritis; Epogen (Erythropoietic Stimulating Agents); Aranesp (darbepoetin alfa) to treat anemia associated with chronic kidn

  • Cardiovascular Disease
  • Lipid Modifying Drug
  • Therapy
  • United States
  • Product Initiative

THE COMPANY HAS A STRONG PRESENCE IN THE RHEUMATOID ARTHRITIS AND ONCOLOGY MARKETS, WITH THE BLOCKBUSTERS ENBREL (ETANERCEPT) AND NEULASTA (PEGFILGRASTIM)/ NEUPOGEN (FILGRASTIM) COMPRISING ITS TOP TWO BESTSELLING THERAPIES IN 2013.

  • Lipid Modifying Drug
  • AstraZeneca PLC
  • GlaxoSmithKline plc
  • Merck & Co., Inc.
  • Pfizer Inc.